The STAR™ Tumor Ablation Registry

Merit Medical Systems

Status: Terminated

Conditions: Metastatic Lesions in Vertebral Bodies

Treatments: Device: STAR™ Tumor Ablation System

Study type: Observational

Funder types: Industry

Identifiers

NCT02419703

DF-15-03

Details and patient eligibility

About

Registry collecting data on use of The STAR™ Tumor Ablation System.

Full description

The STAR Prospective Registry is an observational registry to gather clinical safety and outcome data in patients with painful spinal metastases in the thoracolumbar spine (T1-L5) following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Enrollment: 65 patients

Sex: All

Ages: 22+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae (T1-L5) that will be treated with t-RFA using the STAR™ Tumor Ablation System.
• Have signed informed consent

Exclusion criteria

• Subjects under 18 years old
• Subjects with heart pacemakers, or other electronic device implants
• Subjects intended for t-RFA in vertebral body levels C1-7

Trial design

65 participants in 1 patient group

Patients receiving Targeted Radiofrequency Ablation (t-RFA)

Treatment:

Device: STAR™ Tumor Ablation System